#Coronavirus Disease Research #References (AMEDEO, June 13 '26)

 

Clin Infect Dis

1. BRITT NS, Khader K, He T, Prinzi AM, et al
   Clinical Impact of the BIOFIRE(R) FILMARRAY(R) Pneumonia Panel in the Veterans Affairs Healthcare System: A Difference-in-Differences Study.
   Clin Infect Dis. 2026 Jun 12:ciag328. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

2. NERBY J, Berg W, McFarren M, Rhame F, et al
   Collaborative approaches to masking: statewide threshold development and performance across three respiratory seasons.
   Infect Control Hosp Epidemiol. 2026 Jun 11:1-7. doi: 10.1017/ice.2026.10487.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. CHEN H, Manu EK
   Shifting patterns of acute respiratory infection mortality in Australia: Changing contributions of COVID-19, influenza and respiratory syncytial virus and persistent Indigenous inequalities.
   Int J Infect Dis. 2026 Jun 8:108866. doi: 10.1016/j.ijid.2026.108866.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

4. MEYBOHM P, Baron DM, Fries D, Lasocki S, et al
   Patient blood management in general intensive care patients.
   Intensive Care Med. 2026 Jun 8. doi: 10.1007/s00134-026-08491.
   PubMed         Abstract available
   
   

   
   J Infect

5. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
   Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
   J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
   PubMed         Abstract available
   
   
6. WANG X, Yin J, Xu B, Guanhua X, et al
   Clinical epidemiological characteristics of hospitalized pediatric Mycoplasma pneumoniae pneumonia in China.
   J Infect. 2026 Jun 10:106793. doi: 10.1016/j.jinf.2026.106793.
   PubMed         Abstract available
   
   
7. TRUONG T, Radin JM, Li L, Ordonez-Mena JM, et al
   Burden and economic impact of RSV hospitalisations among English adults, 2023/24.
   J Infect. 2026;93:106792.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. USHIJIMA H, Onda-Shimizu Y, Kotaki T, Nishimura S, et al
   Co-Circulation and Mixed Infections of Classic and Melbourne Human Astroviruses Among Pediatric Acute Gastroenteritis Patients in Japan, 2018-2024.
   J Med Virol. 2026;98:e71002.
   PubMed         Abstract available
   
   
9. AYDIN U, Duzenci D, Akkoc RF, Karatas A, et al
   Serum Histatin Levels in COVID-19: Association With Disease Severity and Immune Status.
   J Med Virol. 2026;98:e71009.
   PubMed         Abstract available
   
   
10. CHEN R, Kong W, Li C, Zhang J, et al
    TXD-198 Exhibits Inhibitory Activity Against SARS-CoV-2 by Upregulating ANO1.
    J Med Virol. 2026;98:e71004.
    PubMed         Abstract available
    
    
11. DENG J, Lin Q, Zeng Z, Huang H, et al
    Post-Pandemic Influenza Resurgence in Guangzhou, China: Impact of COVID-19 Interventions and Immune Alterations.
    J Med Virol. 2026;98:e71012.
    PubMed         Abstract available
    
    
12. FU JYL, Lim SK, Jalalonmuhali M, Bador MK, et al
    Immune Pressure From Plasma From Immunocompromised and Healthy Individuals Drives Differential SARS-CoV-2 Evolution and Escape Mutation Emergence.
    J Med Virol. 2026;98:e71016.
    PubMed         Abstract available
    
    

    
    J Travel Med

13. LUBBERT C, Fruhwein M, Dinjer CS, Machler C, et al
    Assessment of the healthcare burden of dengue disease in Germany: a retrospective analysis of statutory health insurance data (2014-2023).
    J Travel Med. 2026 Jun 11:taag047. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

14. YANG Y, Su Z, Zhang X, Tan Y, et al
    PPP2R5B regulates ANPEP expression and TGEV entry via dephosphorylation of HSF1 at Ser304/Ser308.
    J Virol. 2026 Jun 11:e0016626. doi: 10.1128/jvi.00166.
    PubMed         Abstract available
    
    
15. YO MS, Kaku Y, Kosugi Y, Tolentino JE, et al
    Genetic diversity of pangolin coronaviruses reveals a key immuno-evasive substitution at spike residue 519.
    J Virol. 2026 Jun 10:e0035226. doi: 10.1128/jvi.00352.
    PubMed         Abstract available
    
    
16. PENG M, Liu L, Li X, Yu X, et al
    Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
    J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
    PubMed         Abstract available
    
    
17. ARTUSA V, Limanaqi F, Santacroce E, Clerici M, et al
    Alpha-synuclein at the crossroads of host-virus interactions: immunological roles beyond the nervous system.
    J Virol. 2026 Jun 9:e0019126. doi: 10.1128/jvi.00191.
    PubMed         Abstract available
    
    
18. VARGAS DA, Albornoz LL, Pena-Morales M, Ortiz Rojas HJ, et al
    Within-host SARS-CoV-2 diversity in immunocompromised patients during acute infection.
    J Virol. 2026 Jun 9:e0222425. doi: 10.1128/jvi.02224.
    PubMed         Abstract available
    
    
19. YU H-M, Zhu M-L, Zhao Y-L, Tan J-X, et al
    Research progress on the association between viruses and cardiac diseases.
    J Virol. 2026 Jun 9:e0038326. doi: 10.1128/jvi.00383.
    PubMed         Abstract available
    
    
20. LI S, Luo H, Zhang K, Wu C, et al
    The cholesterol transporter Niemann-Pick C1 facilitates the entry of porcine epidemic diarrhea coronavirus.
    J Virol. 2026 Jun 9:e0030126. doi: 10.1128/jvi.00301.
    PubMed         Abstract available
    
    
21. ZHANG Q, Xin J, Wang C, Zhang X, et al
    Cleavage of TOM1 by the SARS-CoV-2 main protease NSP5 prevents autophagic degradation of viral envelope.
    J Virol. 2026 Jun 12:e0043426. doi: 10.1128/jvi.00434.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

22. XIE Y, Choi T, Al-Aly Z
    Seasonal influenza versus COVID-19 hospitalisation risk during the 2025-26 influenza season.
    Lancet Infect Dis. 2026 Jun 10:S1473-3099(26)00289.
    PubMed        
    
    

    
    Travel Med Infect Dis

23. MIHAI I, Bonnaud L, Arregle F, Doudier B, et al
    Purulent meningococcal pericarditis with cardiac tamponade in a Hajj pilgrim: A diagnostic challenge of anchoring bias on MERS-CoV.
    Travel Med Infect Dis. 2026;72:103001.
    PubMed         Abstract available
    

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 13 '26)

 

Arch Virol

1. SMATTI MK, Al-Khatib H, Suleman M, Nizar M, et al
   Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.
   Arch Virol. 2026;171:198.
   PubMed         Abstract available
   
   

   
   J Infect

2. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
   Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
   J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
   PubMed         Abstract available
   
   
3. CORRAO G, Sguazzini E, Gori A, Monti E, et al
   All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
   J Infect. 2026;93:106769.
   PubMed         Abstract available
   
   
4. GUINOVART LJ, Westrhenen SEMH, Schuurman R, Bruijning-Verhagen PCJL, et al
   Symptomatology of SARS-CoV-2 versus seasonal coronavirus infection in healthy young children.
   J Infect. 2026 May 20:106762. doi: 10.1016/j.jinf.2026.106762.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. LIU F, Gross FL, Li Z, House SL, et al
   Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectiveness.
   J Infect Dis. 2026 Jun 8:jiag294. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

6. LIU Z, Fan M, Zeng Y, Zheng Y, et al
   Gga-miR-92-targeted TNFRSF1B inhibits the replication of influenza A virus by degrading TRAF3.
   J Virol. 2026 Jun 12:e0067426. doi: 10.1128/jvi.00674.
   PubMed         Abstract available
   
   
7. XU S, Zhang Q, Xie X, Zhou M, et al
   A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.
   J Virol. 2026 Jun 11:e0056326. doi: 10.1128/jvi.00563.
   PubMed         Abstract available
   
   
8. PENG M, Liu L, Li X, Yu X, et al
   Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
   J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

9. LIN Z, Gao Y, Sun W
   Supervised deep learning with gene functional annotation for cell classification.
   PLoS Comput Biol. 2026;22:e1014327.
   PubMed         Abstract available
   
   
10. KWON J, Li K, Warren JL, Pandya S, et al
    Utilizing virus genomic surveillance to predict vaccine effectiveness.
    PLoS Comput Biol. 2026;22:e1014329.
    PubMed         Abstract available
    
    

    
    PLoS One

11. TAM VCW, Yeung NCY, Kwok AWL
    Getting over the hurdles to save lives: Incorporating perceived barriers into theory of planned behaviour (TPB) model to predict stated intention among Hong Kong trained laymen.
    PLoS One. 2026;21:e0350392.
    PubMed         Abstract available
    
    
12. KONDO K, Morita I, Sakuma S, Ohsawa I, et al
    Changes in tobacco sales before, during, and after the COVID-19 pandemic in Japan: An interrupted time series analysis.
    PLoS One. 2026;21:e0350820.
    PubMed         Abstract available
    
    
13. WOODGATE RL, Mary-Quigley L, Bell A, Bennett M, et al
    Youth's mental health journeys through the COVID-19 pandemic using arts-based methods in virtual environments.
    PLoS One. 2026;21:e0349860.
    PubMed         Abstract available
    
    
14. KARAMI B, Rezaeian S, Bagherinia M, Shakiba E, et al
    Social support and health related quality of life among older people in covid-19 pandemic: The mediating role of resilience.
    PLoS One. 2026;21:e0342982.
    PubMed         Abstract available
    
    
15. YANG RJ, Wang M, Lyu L, You JL, et al
    Pathogen spectrum and epidemiology of respiratory tract infections in Quzhou, Eastern China, from November 2023 to July 2024: A post?COVID?19 surveillance study.
    PLoS One. 2026;21:e0346441.
    PubMed         Abstract available
    
    
16. BOLSHOV O, Chumachenko D
    Reinforcement learning for policymaking in epidemic control: A scoping review.
    PLoS One. 2026;21:e0351176.
    PubMed         Abstract available
    
    
17. LIU C, Liu H, Wei Y, Ye J, et al
    Modeling the effects of meteorological factors and media-driven public awareness on seasonal influenza outbreaks.
    PLoS One. 2026;21:e0342962.
    PubMed         Abstract available
    
    
18. LIU F, Lai T, Xu W, Li G, et al
    ViralMultiNet: A structure-aware multimodal framework for viral protein function prediction in wastewater surveillance.
    PLoS One. 2026;21:e0349393.
    PubMed         Abstract available
    
    
19. MOUNCHID PM, Shukla S, Steinert JI
    The interplay of economic shocks and cultural practices in child marriage: Comparative evidence from India and Zambia during the COVID-19 pandemic.
    PLoS One. 2026;21:e0346851.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. ZHU Z, Fragkias M, Suh JW, McCoshan E, et al
    The Urban Pulse: Diagnosing the urbanization process as spiky, cyclical, and asynchronous.
    Proc Natl Acad Sci U S A. 2026;123:e2537770123.
    PubMed         Abstract available
    
    
21. SKELLY AN, Fan C, Keeffe JR, Okten AB, et al
    mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.
    Proc Natl Acad Sci U S A. 2026;123:e2536870123.
    PubMed         Abstract available
    
    

    
    Vaccine

22. WU X, Tao Y, Sun Y, Chen J, et al
    Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data.
    Vaccine. 2026;88:128782.
    PubMed         Abstract available
    
    
23. BIETZ A, Sandow P, Hartmann C, Steffan L, et al
    Real-time in-season monitoring of adult influenza vaccination coverage rates in Germany: results from a repeated cross-sectional online survey.
    Vaccine. 2026;88:128765.
    PubMed         Abstract available
    
    
24. SONG L, He G, Cui Y, Tan R, et al
    Optimized flagellin enhances systemic and mucosal immune responses induced by SARS-CoV-2 virus-like particle vaccines.
    Vaccine. 2026;87:128767.
    PubMed         Abstract available
    
    
25. FAIJUE DD, Bouaddi O, Segui AO, Morias B, et al
    Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis.
    Vaccine. 2026;85:128645.
    PubMed         Abstract available
    
    
26. FORNS J, Pajouheshnia R, Aurelius T, Bouck Z, et al
    Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.
    Vaccine. 2026;86:128723.
    PubMed         Abstract available
    
    
27. POWELL A, Suwalowska H, Sankoh O, Guo C, et al
    Recent enough to matter: Perceived temporal proximity, anxiety, and COVID-19 vaccine intent.
    Vaccine. 2026;85:128717.
    PubMed         Abstract available
    
    
28. DALEXIS RD, Beogo I, Kibret TC, Cenat JM, et al
    Racial disparities in coverage and determinants of childhood diphtheria, tetanus, and pertussis (DTaP) vaccination in Canada: a post-COVID-19 pandemic analysis.
    Vaccine. 2026;85:128679.
    PubMed         Abstract available
    
    
29. KOIRALA A, Prasad SA, Tjiam MC, Britton PN, et al
    SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.
    Vaccine. 2026;85:128705.
    PubMed         Abstract available
    
    
30. XU Y, Nyberg F, Marking U, Gisslen M, et al
    Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
    Vaccine. 2026;85:128724.
    PubMed         Abstract available
    
    
31. DANCHIN M, Rak A, Vasiliadis S, Wang B, et al
    Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice experiment.
    Vaccine. 2026;85:128710.
    PubMed         Abstract available
    
    
32. KOHLI M, Maschio M, Lee A, Kissler S, et al
    The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.
    Vaccine. 2026;85:128687.
    PubMed         Abstract available
    
    
33. TRANG TPH, Bazelier MT, Klungel OH, Bots SH, et al
    Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.
    Vaccine. 2026;85:128722.
    PubMed         Abstract available
    
    
34. WANG R, Zhao Y, Yang J, Luo R, et al
    Systemic BCG administration induces transcription factor signature in CD4(+) T cells that cooperates with IL-12 signaling to drive antiviral Th1 differentiation.
    Vaccine. 2026;85:128720.
    PubMed         Abstract available
    
    

    
    Virology

35. KOVACS E, Rios Carrasco M, Guerreiro Cabana MF, de Vries RP, et al
    H5N1 2.3.4.4b HA E190D and Q226H mutations, picked up as minority variants in a patient, result in an inability to bind sialic acid.
    Virology. 2026;621:110949.
    PubMed         Abstract available
    
    

    
    Virus Res

36. TJARNHAGE E, Vatsveen TK, Raki M, Nemazee D, et al
    Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).
    Virus Res. 2026 Jun 9:199759. doi: 10.1016/j.virusres.2026.199759.
    PubMed         Abstract available
    

Seasonal #influenza versus #COVID19 #hospitalisation #risk during the 2025–26 influenza season

 

{Excerpt}

(...)

Contemporary surveillance data have shown higher population rates of influenza infections and hospitalisations during the 2025–26 influenza season; however, these aggregate metrics cannot disentangle infection frequency from disease severity. This analysis extends that evidence by comparing outcomes on a per-infection basis among patients with multiplex-based, laboratory-confirmed infection, showing that seasonal influenza was associated with a 43% higher risk of hospitalisation than COVID-19, corresponding to approximately 48 additional hospitalisations per 1000 infected individuals. The higher severity associated with seasonal influenza during this season likely reflects a combination of factors, including the increased virulence of circulating influenza strains, mismatch between vaccine composition and dominant circulating influenza variants, and the continued attenuation of SARS-CoV-2 severity over successive waves.

(...)

Source: 

Link: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00289-6/fulltext?rss=yes

____

#Taiwan reported a rise in domestic #COVID19 cases, public is invited to wear masks as needed (CDC, June 9 '26)

 

    The Taiwan Centers for Disease Control (CDC) stated today (June 9th) that, according to monitoring data, the domestic COVID-19 epidemic has been rising from its low point. 

    In the 22nd week (May 31st - June 6th), there were 1,000 outpatient and emergency room visits related to COVID-19, a 4.1% increase compared to the previous week. 

    Last week (June 2nd - June 8th), there were 5 new local cases of severe COVID-19 complications, with no new local deaths. 

    Since October 2025, there have been a cumulative total of 90 local cases of severe COVID-19 complications, of which 14 have died. 

    The majority of severe cases are among those aged 65 and above (72.2%) and those with a history of chronic diseases (81.1%), and 93.3% have not received the COVID-19 vaccine this season.

    The Centers for Disease Control (CDC) pointed out that the global COVID-19 positivity rate has recently risen slightly from its low point. 

    The predominant circulating variants are BA.3.2 and XFG, followed by NB.1.8.1. 

    Among all regions, Southeast Asia has seen a significant increase. 

    The epidemic in neighboring countries is rising in India, the epidemic in Singapore is fluctuating from its peak, the epidemic in China is rising slightly from its low point, and the epidemic in Japan is flat from its low point.

    The Taiwan Centers for Disease Control (CDC) reminds the public that with the rise of COVID-19 cases in Taiwan, it urges the public to strengthen their self-protection awareness, practice hand hygiene and respiratory etiquette. 

    To protect their own health and the health of others, if they experience respiratory symptoms such as fever, cough, runny nose, or sore throat, or when visiting healthcare facilities, in crowded places where social distancing is difficult or poorly ventilated, or in close contact with the elderly or immunocompromised individuals, it is recommended to wear a mask. 

    If you have a fever or respiratory symptoms, it is advised to stay home and avoid unnecessary outings. 

    Those with severe risk factors and who meet the criteria for publicly funded antiviral medication should seek medical attention as soon as possible if they experience suspected symptoms. 

    A doctor will assess the symptoms and prescribe antiviral medication to reduce the risk of serious complications or death after infection. 

    Furthermore, the CDC urges those who have not yet received this season's COVID-19 vaccine within the past six months to get vaccinated as soon as possible.

    The Centers for Disease Control (CDC) emphasizes that there are currently sufficient reserves of COVID-19 vaccines and antiviral drugs. 

    For inquiries about vaccination sites, contracted hospitals for publicly funded oral antiviral drugs, and the latest epidemic prevention policies, the public can visit the CDC website (https://www.cdc.gov.tw) or call the toll-free epidemic prevention hotline 1922 (or 0800-001922).

Source: 

Link: https://www.cdc.gov.tw/Bulletin/Detail/gyc9j6zazoe_7nR9FqdFYQ?typeid=9

____

#Human ACE2‑specific benzothiazole-based allosteric #inhibitor against pan ‑ #sarbecoviruses

 

Abstract

Emerging SARS‑CoV‑2 variants and related zoonotic sarbecoviruses rely on ACE2 for cell entry, motivating host‑directed antivirals that block spike-ACE2 interaction. Here, we characterize MB‑32, a benzothiazole small molecule that binds ACE2, selectively disrupts binding of SARS‑CoV‑2 spike receptor‑binding domain to ACE2, and preserves ACE2 enzymatic activity across species. MB‑32 potently inhibits entry of SARS‑CoV‑2 variants, SARS‑CoV‑1 and diverse bat/pangolin sarbecoviruses in ACE2‑expressing cells, while sparing vesicular stomatitis virus and authentic MERS‑CoV, indicating non‑virucidal, ACE2‑focused activity. Biochemical and biophysical analyses, supported by ACE2 mutagenesis, support a model in which MB‑32 engages a non‑catalytic surface pocket on the ACE2 N‑terminal helix to allosterically disrupt spike attachment. Intranasal MB‑32 achieves high airway concentrations, protects male ACE2‑transgenic mice and hamsters from SARS‑CoV‑2 disease, and prevents contact transmission of Omicron‑lineage viruses without detectable cardiovascular toxicity. These findings establish MB‑32 as a host‑targeted ACE2 entry inhibitor and provide a framework for small‑molecule ACE2‑directed antivirals against current and future sarbecovirus spillovers.

Source: 

Link: https://www.nature.com/articles/s41467-026-73944-x

____

#Coronavirus Disease Research #References (AMEDEO, June 6 '26)

 

Ann Intern Med

1. KOUTOURATSAS T, Dammad T, Mylonakis E
   In outpatients with COVID-19 during Omicron variant circulation, some antivirals reduce time to recovery.
   Ann Intern Med. 2026 Jun 2. doi: 10.7326/ANNALS-26-01878.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. BONTEN M, Essink B, Hanning N, Leroux-Roels I, et al
   Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged >/=50 years: a phase 3, randomized, non-inferiority trial.
   Clin Infect Dis. 2026 Jun 4:ciag344. doi: 10.1093.
   PubMed         Abstract available
   
   
3. BRAMANTE CT, Stewart TG, Boulware DR, McCarthy MW, et al
   Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.
   Clin Infect Dis. 2026 Jun 4:ciag335. doi: 10.1093.
   PubMed         Abstract available
   
   
4. LIU C, Okoli GN, Chen R, Sullivan SG, et al
   SARS-CoV-2 vaccination and attenuation of breakthrough infection severity: A systematic global review and meta-analysis.
   Clin Infect Dis. 2026 Jun 1:ciag346. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

5. JURICA JM, Smith DM, Abeles S, Torriani FJ, et al
   Discontinuing contact precautions for COVID-19: the science says its time.
   Infect Control Hosp Epidemiol. 2026 Jun 5:1-3. doi: 10.1017/ice.2026.10482.
   PubMed         Abstract available
   
   
6. ALSOUBANI M, Andujar G, Campion M
   Socioeconomic and racial review of COVID-19 antiviral prescriptions: a large health system cohort.
   Infect Control Hosp Epidemiol. 2026 Jun 1:1-6. doi: 10.1017/ice.2026.10473.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

7. VEIJER C, van Asselt ADI, van Zon SKR, Rosmalen JGM, et al
   Healthcare Resource Use and Costs under Pandemic Circumstances in The Netherlands: Results from the Lifelines COVID-19 Cohort.
   Int J Infect Dis. 2026 Jun 3:108854. doi: 10.1016/j.ijid.2026.108854.
   PubMed         Abstract available
   
   
8. ABU-RADDAD LJ, Ayoub HH, Coyle P, Tang P, et al
   Routine SARS-CoV-2 Testing Frequency and Risk of Severe COVID-19: A Nationwide Population-Based Study.
   Int J Infect Dis. 2026 Jun 2:108851. doi: 10.1016/j.ijid.2026.108851.
   PubMed         Abstract available
   
   
9. LAW AHT, Wong JY, Lin Y, Cowling BJ, et al
   Sex differences in COVID-19 infection and mortality in Hong Kong.
   Int J Infect Dis. 2026 Jun 2:108852. doi: 10.1016/j.ijid.2026.108852.
   PubMed         Abstract available
   
   
10. LIN Y, Wu P, Lau EHY, Blais J, et al
    SARS-CoV-2 viral shedding and vaccination?modified effects of oral antivirals in older COVID-19 patients: a retrospective cohort study in Hong Kong.
    Int J Infect Dis. 2026 Jun 1:108848. doi: 10.1016/j.ijid.2026.108848.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. CHEN Y, Lan Y, Zhao A, Zhang Y, et al
    Anti-Zika Virus Activity of Azvudine via Inhibition of RNA Replication by Its Active Triphosphate Form.
    J Med Virol. 2026;98:e71000.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

12. XU X, Saad MB, Grippin A, Xu H, et al
    Brief Report: SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated with Radiotherapy.
    J Thorac Oncol. 2026 Jun 1:103956. doi: 10.1016/j.jtho.2026.103956.
    PubMed         Abstract available
    
    

    
    J Virol

13. FAN L, Gao X, Feng W, Huang Q, et al
    SARS-CoV-2 ORF3a suppresses host antiviral interferon responses by promoting STUB1-mediated PTEN proteasomal degradation.
    J Virol. 2026 Jun 2:e0018626. doi: 10.1128/jvi.00186.
    PubMed         Abstract available
    
    

    
    Lancet

14. KARIM SA, Mahomed S, Lewis L, Karim SSA, et al
    Urgent need for a reliable rapid diagnostic test for the Ebola epidemic caused by Bundibugyo virus in Africa.
    Lancet. 2026 Jun 2:S0140-6736(26)01093-7. doi: 10.1016/S0140-6736(26)01093.
    PubMed        
    
    

    
    Lancet Infect Dis

15. 
    Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet Infect Dis. 2026 Jun 2:S1473-3099(26)00194.
    PubMed         Abstract available
    
    

    
    Science

16. EMANUEL N, Harrington E, Pallais A
    Home alone: Remote work, isolation, and mental health.
    Science. 2026;392:eaec7671.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 6 '26)

 

Arch Virol

1. PERDANA WY, Tsuneki-Tokunaga A, Rahmi KA, Hinay AA Jr, et al
   In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.
   Arch Virol. 2026;171:200.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. SHAO S, Dong ZY, Kang ZY, Zhang H, et al
   Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines.
   Biochem Biophys Res Commun. 2026;825:153958.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

3. SANE J
   Rebuilding trust in public health: Beyond polarization.
   Epidemiol Infect. 2026;154:e71.
   PubMed         Abstract available
   
   
4. HASSELL K, Andrews N, Dabrera G, Kall M, et al
   Acute COVID-19 mortality in England in the omicron era: a national-level matched cohort study.
   Epidemiol Infect. 2026;154:e70.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. PRASERT K, Praphasiri P, Ditsungnoen D, Naosri S, et al
   Risk of hospitalization related to influenza A(H3N2) virus subclade K, Thailand, June-December 2025.
   J Infect Dis. 2026 May 31:jiag283. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Neurosurg Pediatr

6. ANDERSON MG, Pindrik J, Michelow IC, Anuar A, et al
   Pediatric sinogenic and otogenic intracranial infections requiring neurosurgical intervention: a North American multicenter study in the era of COVID-19.
   J Neurosurg Pediatr. 2026;37:621-631.
   PubMed         Abstract available
   
   

   
   J Virol

7. 
   CEIRR Risk Assessment Pipeline executive reports on H5N1 highly pathogenic avian influenza 2.3.4.4b, swine H1 1B.2, and H9N2 low pathogenicity avian influenza B4.7.2.
   J Virol. 2026 Jun 3:e0054526. doi: 10.1128/jvi.00545.
   PubMed         Abstract available
   
   
8. STEARNS K, Marcink T, Pawlack E, Sobolik EB, et al
   Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread.
   J Virol. 2026 Jun 3:e0212625. doi: 10.1128/jvi.02126.
   PubMed         Abstract available
   
   
9. TURNER AH, Jaffrani SA, Kubinski HC, Ajayi DP, et al
   Rab11B is required for binding and entry of recent H3N2, but not H1N1, influenza A isolates.
   J Virol. 2026 Jun 2:e0211125. doi: 10.1128/jvi.02111.
   PubMed         Abstract available
   
   

   
   Pediatrics

10. ROSTAD CA, Healy CM, Nayak JL, Parameswaran L, et al
    Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.
    Pediatrics. 2026 May 4:e2025075223. doi: 10.1542/peds.2025-075223.
    PubMed         Abstract available
    
    

    
    PLoS One

11. EKWUNIFE O, Mangenah C, Ngwira L, Corbett E, et al
    Economic barriers to diagnostic equity: A multi-country analysis of patient costs for rapid SARS-CoV-2 testing in sub-Saharan Africa.
    PLoS One. 2026;21:e0350288.
    PubMed         Abstract available
    
    
12. HEMBERG M, Hansen AL, Storgaard J, Blay-Cadanet J, et al
    MAVS is important for antiviral defense against influenza A virus in a human respiratory epithelium model.
    PLoS One. 2026;21:e0350839.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

13. RIKANI A, Di Domenico L, Sabbatini CE, Navarro V, et al
    Resetting population mobility responses under repeated nonpharmaceutical interventions: Implications for hypothesized pandemic fatigue.
    Proc Natl Acad Sci U S A. 2026;123:e2533284123.
    PubMed         Abstract available
    
    
14. PAPADAKI M, Pavlos E, Dubourdeau M, Bailif V, et al
    Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.
    Proc Natl Acad Sci U S A. 2026;123:e2534726123.
    PubMed         Abstract available
    
    
15. GRUNDY JG, Pujols-Beltran M
    Bilingualism predicts executive function resilience after COVID-19 in aging.
    Proc Natl Acad Sci U S A. 2026;123:e2532470123.
    PubMed         Abstract available
    
    

    
    Vaccine

16. DE FIGUEIREDO A, Paterson P, Lin L, Mounier-Jack S, et al
    Changing socio-demographic determinants of seasonal influenza acceptance in England during the pandemic and a framework for predicting future acceptance.
    Vaccine. 2026;85:128629.
    PubMed         Abstract available
    
    
17. DAS S, Tenaglia BM, Riley D, Speed S, et al
    BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy.
    Vaccine. 2026;87:128774.
    PubMed         Abstract available
    
    

    
    Virus Res

18. SEDAGHAT M, Najafi F, Khosravi Shademani F, Rezaeian S, et al
    Seasonal influenza vaccine and frequency of adverse events in health workers receiving two doses of AstraZeneca vaccine: a retrospective cohort study.
    Virus Res. 2026;369:199757.
    PubMed         Abstract available

#SARS-CoV-2 #Omicron BA.2.86 and JN.1 expand #tropism in #human proximal #intestinal epithelium

 

Abstract

Omicron SARS-CoV-2 has diversified into multiple sub-lineages, complicating assessment of their intrinsic phenotypes due to background population immunity. We compare replication and biological characteristics of variants from BA.1 to JN.1 using human bronchial and lung explants, airway organoids, colon cells, and proximal intestinal enteroids. XBB.1.5 and EG.5.1 achieve higher replication titres in respiratory tissues than BA.2.86 and JN.1, indicating enhanced respiratory fitness. EG.5.1 displays dual cell-entry pathways and greater replication in alveolar epithelial cells, supporting increased lung tropism and pathogenicity. In contrast, BA.2.86 and JN.1 rely on TMPRSS2-mediated entry in airways. Notably, BA.2.86 and JN.1 replicate more efficiently than EG.5.1 in proximal intestinal enteroids in an ACE2- and TMPRSS2-dependent manner, but not in colon cells. JN.1 exhibits elevated intestinal tropism with limited proinflammatory cytokine induction, suggesting potential for faecal transmission. Here we show XBB.1.5 and EG.5.1 greater transmissibility and severity potential whereas BA.2.86 and JN.1 exhibit enhanced intestinal adaptation.

Source: 

Link: https://www.nature.com/articles/s41467-026-74111-y

____

Identification and characterization of a #SARS-CoV-2 #Mpro G23 deletion #ensitrelvir - #resistant mutant

 

ABSTRACT

Ensitrelvir is an antiviral drug that specifically targets the conserved main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, mutations in Mpro could confer resistance to antivirals, including ensitrelvir. Thus, identifying SARS-CoV-2 drug-resistant mutants and elucidating their mechanisms of resistance are critical for guiding the selection of effective antiviral therapies. Here, we utilized a recombinant luminescent attenuated SARS-CoV-2 lacking the open reading frames (ORF) 3a and 7b proteins (Δ3a7b-Nluc WT) to safely identify ensitrelvir drug-resistant mutants (DRM-E) without the need of using virulent forms of SARS-CoV-2. We isolated a DRM-E containing a Mpro G23 deletion (G23del) with high resistance (~1,000-fold) to ensitrelvir, but not to the Mpro inhibitor nirmatrelvir or to the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir. The contribution of G23del in ensitrelvir resistance was confirmed by generating a Δ3a7b-Nluc containing G23del in Mpro (Δ3a7b-Nluc G23del). Δ3a7b-Nluc G23del exhibited resistance to ensitrelvir in both cultured cells and in K18 hACE2 transgenic mice. Binding affinity revealed that the G23del mutation altered ensitrelvir, but not nirmatrelvir, binding to Mpro. Notably, while Δ3a7b-Nluc G23del was affected in viral fitness, serial passage of Δ3a7b-Nluc G23del in the absence of ensitrelvir resulted in the emergence of substitution L50F in Mpro that restored viral fitness loss caused by G23del without altering resistance to ensitrelvir. Our results demonstrate that G23del in Mpro can confer resistance to ensitrelvir. Positively, G23del in Mpro does not render SARS-CoV-2 resistant to nirmatrelvir or remdesivir, suggesting the feasibility of treating SARS-CoV-2 infections containing G23del Mpro with other approved antivirals.

Source: 

Link: https://journals.asm.org/doi/10.1128/mbio.00584-26

____

#Coronavirus Disease Research #References (AMEDEO, May 30 '26)

 

Antiviral Res

1. MALOCCU S, Otsuka Y, Molchan E, Foti M, et al
   Identification of Nsp15 inhibitors restoring interferon-dependent antiviral activity against SARS-CoV-2.
   Antiviral Res. 2026;251:106443.
   PubMed         Abstract available
   
   

   
   BMJ

2. YAMEY G
   Trump and RFK Jr have a new approach to global health: holding vulnerable people to ransom.
   BMJ. 2026;393:e387444.
   PubMed        
   
   

   
   Graefes Arch Clin Exp Ophthalmol

3. XU X, Yu P, Wu S, Wang L, et al
   Repeatability of corneal diameter measured by Sirius versus IOLMaster 700 in myopic eyes: combined with consistency and relationship of sulcus-to-sulcus.
   Graefes Arch Clin Exp Ophthalmol. 2026 May 23. doi: 10.1007/s00417-026-07281.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

4. GIBAS KM, Head T, Broadley M, Mermel LA, et al
   Healthcare personnel masking: current practices and gaps in standardized thresholds.
   Infect Control Hosp Epidemiol. 2026 May 26:1-8. doi: 10.1017/ice.2026.10469.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. BRUNVOLL SH, Fagerland MW, Nygaard AB, Ellingjord-Dale M, et al
   Long COVID symptoms before and 3-35 Months after SARS-CoV-2 infection in a Norwegian prospective cohort study, symptoms over the pandemic and different virus variants.
   Int J Infect Dis. 2026 May 27:108822. doi: 10.1016/j.ijid.2026.108822.
   PubMed         Abstract available
   
   

   
   J Infect

6. LU L, Long Z, Chen F, Li Z, et al
   Global Disability-Adjusted Life Years Burden of Lower Respiratory Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae, 1990-2021: A Systematic Analysis of the Global Burden of Disease Study 2021.
   J Infect. 2026 May 25:106768. doi: 10.1016/j.jinf.2026.106768.
   PubMed         Abstract available
   
   
7. CORRAO G, Sguazzini E, Gori A, Monti E, et al
   All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
   J Infect. 2026;93:106769.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. 
   Correction to "Deep Sequencing Reveals Dual Evolution of SARS-CoV-2: Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants".
   J Med Virol. 2026;98:e70987.
   PubMed        
   
   
9. REPUSIC D, Korolija M, Livun A, Svagusa T, et al
   Multi-Layered Genomic and Clinical Analysis Identifies Novel Variants, Co-Occurring Single Nucleotide Polymorphism Pairs, and Clinical Determinants of Host-Pathogen Interaction in COVID-19 Severity.
   J Med Virol. 2026;98:e70984.
   PubMed         Abstract available
   
   

   
   Lancet

10. GIOVANNONI G, Airas L, Bove R, Cutter GR, et al
    Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
    Lancet. 2026;407:2195-2207.
    PubMed         Abstract available
    
    

    
    N Engl J Med

11. ZIMMERMANN WH, Ensminger S, Kutschka I, Paitazoglou C, et al
    Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.
    N Engl J Med. 2026;394:1991-2001.
    PubMed         Abstract available
    
    

    
    Nature

12. SUZUKI R, Yamasoba D, Kimura I, Wang L, et al
    Author Correction: Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
    Nature. 2026 May 29. doi: 10.1038/s41586-026-10665.
    PubMed        
    
    
13. ZENG AGX, Nagree MS, Jakobsen NA, Shah S, et al
    Human haematopoietic stem cells remember inflammatory stress.
    Nature. 2026 May 27. doi: 10.1038/s41586-026-10522.
    PubMed         Abstract available
    
    

    
    Radiology

14. SPOSATO A, Mazzola MA, Kunst MM
    Case 346: gamma-Aminobutyric Acid A Receptor Encephalitis.
    Radiology. 2026;319:e251976.
    PubMed         Abstract available
    

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 30 '26)

 

Cell

1. DE SA KSG, Silva J, Bayarri-Olmos R, Baker CA, et al
   A causal link between autoantibodies and neurological symptoms in long COVID.
   Cell. 2026;189:3214-3235.
   PubMed         Abstract available
   
   
2. WALL EC, Richter AG
   Autoantibodies in long COVID: A mechanistic foothold in a heterogeneous disease.
   Cell. 2026;189:3179-3180.
   PubMed         Abstract available
   
   
3. FOURNIER M, Vanderkerken M, Dorgham K, Bastard P, et al
   Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.
   Cell. 2026;189:3236-3253.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

4. KITAMURA N, Kondo N, Ith S, Okuyama M, et al
   Post-pandemic immunity debt for paediatric infectious diseases in Japan between 2014 and 2024.
   Epidemiol Infect. 2026;154:e67.
   PubMed         Abstract available
   
   

   
   J Immunol

5. WANG Q, McManus LR, Levine KS, Blanc R, et al
   A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.
   J Immunol. 2026;215:vkag106.
   PubMed         Abstract available
   
   

   
   J Infect

6. WEE LE, Ho RWL, Lim JT, Lim SK, et al
   Real-world effectiveness of influenza vaccination amongst children aged under 5 in a tropical setting.
   J Infect. 2026 May 26:106771. doi: 10.1016/j.jinf.2026.106771.
   PubMed         Abstract available
   
   
7. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
   A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
   J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
   PubMed         Abstract available
   
   
8. KIM HK, Jo S, Min KD, Cho SI, et al
   Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in Patients With Cancer: Evidence From a Nationwide Target Trial Emulation.
   J Infect. 2026 Apr 28:106753. doi: 10.1016/j.jinf.2026.106753.
   PubMed         Abstract available
   
   

   
   J Virol

9. LOES AN, Tarabi RAL, Li SH, Atkinson RK, et al
   Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.
   J Virol. 2026 May 27:e0031726. doi: 10.1128/jvi.00317.
   PubMed         Abstract available
   
   

   
   J Virol Methods

10. ZENG Q, Liu L, Wang T, Zhang C, et al
    Artificial intelligence-assisted technology to reduce turnaround time for rapid diagnosis of infectious diseases.
    J Virol Methods. 2026;344:115392.
    PubMed         Abstract available
    
    

    
    PLoS Biol

11. ZHOU F, Periasamy S, Jackson ND, Cheng WS, et al
    Redundant and distinct mechanisms suppress innate immune activation during SARS-CoV-2 infection.
    PLoS Biol. 2026;24:e3003808.
    PubMed         Abstract available
    
    

    
    PLoS Med

12. JANSEN E, Bockstal V, Herschke F, Olsson Gisleskog P, et al
    Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.
    PLoS Med. 2026;23:e1004609.
    PubMed         Abstract available
    
    

    
    PLoS One

13. SILVA-VALENCIA J, Tu K, Moineddin R, Butt DA, et al
    Trends in pulmonary exercise testing utilization after the COVID-19 pandemic in Ontario: A population-cohort study.
    PLoS One. 2026;21:e0349020.
    PubMed         Abstract available
    
    
14. WARNE DJ, Varghese A, Brewster A, Browning AP, et al
    Bayesian uncertainty quantification to identify population level vaccine hesitancy behaviours.
    PLoS One. 2026;21:e0349499.
    PubMed         Abstract available
    
    
15. AKIN HY, Tuncali T, Gencer EB, Cengiz Seval G, et al
    Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.
    PLoS One. 2026;21:e0345137.
    PubMed         Abstract available
    
    
16. SIROTIAK Z, Oberhauser AM, Sirotiak AM, Nettleton KA, et al
    Exploring the perceived impact of physical activity on physical and mental health among individuals with long COVID: A qualitative interview inquiry.
    PLoS One. 2026;21:e0350121.
    PubMed         Abstract available
    
    
17. FIORE E, Taio G, Morandi N, Mazzotta E, et al
    Lung ultrasonography to assess efficacy of intranasal and parenteral vaccinations for bovine respiratory disease (BRD) in dairy calves.
    PLoS One. 2026;21:e0349953.
    PubMed         Abstract available
    
    
18. AGYEI G, El-Duah P, Dumevi RM, Muzeniek T, et al
    Serological responses to SARS-CoV-2 in urban and rural Ghana: Antibody waning and implications for long-term population immunity.
    PLoS One. 2026;21:e0348281.
    PubMed         Abstract available
    
    
19. ROSSI SL, Cheng DM, Sereda Y, Truong V, et al
    COVID-19 pandemic-related stress and substance use behaviors among people with HIV - a mixed method analysis.
    PLoS One. 2026;21:e0349567.
    PubMed         Abstract available
    
    
20. YEO HY, Park JY, Marsh S, Castelino L, et al
    Evidence mapping of preference elicitation for non-pharmaceutical interventions targeting respiratory viral transmission: A scoping review protocol.
    PLoS One. 2026;21:e0344828.
    PubMed         Abstract available
    
    
21. KUBILIUTE I, Zaboras E, Majauskaite F, Urboniene J, et al
    Predicting severe COVID-19 disease in adults: A single-centre cohort study during the first three pandemic waves in 2020-2021 in Vilnius, Lithuania.
    PLoS One. 2026;21:e0350112.
    PubMed         Abstract available
    
    
22. BRIDGMAN WH, Safta C, Ray J
    A scalable variational method for estimating the latent infection-rate field of an outbreak.
    PLoS One. 2026;21:e0350090.
    PubMed         Abstract available
    
    
23. STOTZER E, Graner S, Sengpiel V, Wessberg A, et al
    Crisis leadership and strategic decisions in Swedish maternity care during the COVID-19 pandemic: A deductive analysis from the COPE staff project.
    PLoS One. 2026;21:e0346625.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

24. ADIGA A, Chopra A, Wilson ML, Ravi SS, et al
    A high-resolution, US-scale digital similar of interacting livestock, wild birds, and human ecosystems for multihost epidemic spread.
    Proc Natl Acad Sci U S A. 2026;123:e2507074123.
    PubMed         Abstract available
    
    

    
    Vaccine

25. JUFUKU R, Shinchi H, Murata K, Chan M, et al
    TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.
    Vaccine. 2026;86:128762.
    PubMed         Abstract available
    
    
26. LIU R, Fan Y, Xiong S, Lin J, et al
    Drivers of and implementation strategies for influenza vaccination for cardiovascular populations in China: a scoping review.
    Vaccine. 2026;86:128761.
    PubMed         Abstract available
    
    
27. OKUBO Y, Honjyo R, Uda K, Miyairi I, et al
    Nationwide survey for household preparedness and vaccination acceptance during a novel influenza pandemic scenario in Japan, 2025.
    Vaccine. 2026;86:128738.
    PubMed         Abstract available
    
    
28. MYBURGH L, van Loon K, Koetsier J, Hansen Q, et al
    Conjugate vaccine technology enhances responses to influenza virus.
    Vaccine. 2026;86:128728.
    PubMed         Abstract available
    
    
29. HALFMANN PJ, Duffy A, Wang T, Kawaoka Y, et al
    Evaluating the immunogenicity of clade 2 and clade 3 sarbecovirus spike protein nanoparticle vaccines in Syrian hamsters.
    Vaccine. 2026;84:128653.
    PubMed         Abstract available
    
    
30. LAMBERT D, Luisi N
    Prevalence and correlates of COVID-19 vaccine uptake among sexual and gender minority adolescents in the southern United States.
    Vaccine. 2026;84:128661.
    PubMed         Abstract available
    
    
31. SHEN Y, Shahn Z, Robertson MM, Gebo K, et al
    Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort.
    Vaccine. 2026;84:128666.
    PubMed         Abstract available
    
    
32. MULLER MP, Soe P, Shulha HP, Isenor JE, et al
    mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network.
    Vaccine. 2026;84:128630.
    PubMed         Abstract available
    
    
33. AMOAKO N, Cohuet S, Adjei MR, Gurry C, et al
    COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.
    Vaccine. 2026 Feb 17:128310. doi: 10.1016/j.vaccine.2026.128310.
    PubMed         Abstract available
    
    
34. BALAM S, Kane F, Traore B, Konate D, et al
    Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
    Vaccine. 2025 Sep 1:127680. doi: 10.1016/j.vaccine.2025.127680.
    PubMed         Abstract available
    
    
35. GREY-JOHNSON M, Muhammad AK, Sillah F, Jones CJ, et al
    COVID-19 testing acceptance among symptomatic individuals screened for a randomized clinical trial in The Gambia.
    Vaccine. 2026;77 Suppl 1:127608.
    PubMed         Abstract available
    
    
36. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    PubMed         Abstract available
    
    
37. GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
    Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
    Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
    PubMed         Abstract available
    
    
38. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    PubMed         Abstract available
    
    
39. KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
    COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
    Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
    PubMed         Abstract available
    
    
40. ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
    Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
    Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
    PubMed         Abstract available
    
    
41. SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
    Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
    Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
    PubMed         Abstract available
    
    
42. CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
    Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
    Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
    PubMed         Abstract available
    
    
43. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    PubMed         Abstract available
    
    

    
    Virology

44. UNO N, Ross TM
    Intramuscular administration of influenza hemagglutinin in one hind leg elicits similar protective immune responses as administration in two hind legs.
    Virology. 2026;621:110961.
    PubMed         Abstract available
    
    

    
    Virus Res

45. FARSIU N, Mahani FK, Arefinia N, Charostad J, et al
    From Legacy to Innovation: A Comprehensive Review of Vaccine Platforms Against Viral Infections.
    Virus Res. 2026 Apr 16:199730. doi: 10.1016/j.virusres.2026.199730.
    PubMed         Abstract available
    
    
46. VAN DIJK LLA, Rijsbergen LC, Havelaar AC, den Hartog Y, et al
    Innate airway responses shape permissiveness to human respiratory syncytial virus.
    Virus Res. 2026;368:199734.
    PubMed         Abstract available
    
    
47. JANGJOU A, Izadpanah P, Moqhadas M, Faramarzi H, et al
    QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study.
    Virus Res. 2026;368:199739.
    PubMed         Abstract available